SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!
清脆的大开
Lv5
1
910 积分
2024-01-02 加入
最近求助
最近应助
互助留言
Designing proteins with language models
5天前
已完结
The dynamic role of platelets in cancer progression and their therapeutic implications
8天前
已完结
Molecular profile of bladder cancer progression to clinically aggressive subtypes
24天前
已完结
Molecular profile of bladder cancer progression to clinically aggressive subtypes
24天前
已完结
The co-expression of antigen targets as a rationale for ADCs combination in urothelial cancer
25天前
已完结
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial
28天前
已完结
Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
28天前
已完结
First line management of metastatic urothelial cancer: Current and future perspectives after the EV-302 and CheckMate-901 studies
28天前
已完结
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
29天前
已完结
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study
29天前
已完结
没有进行任何应助
无帮助【积分已退回】
4个月前
doi识别错误【积分已退回】
4个月前
doi错误
4个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论